Merck spotlights new peer-reviewed data on gilvetmab
Bottom line
Merck Animal Health said October 1, 2026, that two peer-reviewed papers on gilvetmab, a caninized anti-PD-1 monoclonal antibody for dogs, have now been published in the Journal of Veterinary Internal Medicine and the Journal of the American Veterinary Medical Association. The company framed the publications as a milestone for canine oncology, highlighting clinical data in dogs with melanoma and mast cell tumors, two indications for which gilvetmab is conditionally licensed by the USDA in the U.S. Gilvetmab has been available to board-certified veterinary oncologists since 2023, but these publications add peer-reviewed evidence to a product that has so far been marketed under a conditional biologics pathway. (merck-animal-health.com)
Why it matters: For veterinary professionals, the key change isn’t a new approval, but stronger published evidence behind an already available immunotherapy option. Merck says the JVIM study evaluated objective response, disease control, safety, and immune dynamics in dogs with oral and cutaneous melanoma and mast cell tumor, while USDA product-summary materials show the biologic was licensed based on studies in 51 dogs treated by IV infusion every 14 or 28 days for up to 10 treatments. The regulatory context also matters: gilvetmab is USDA-licensed as a veterinary biologic, not FDA-approved as a conventional drug, and guideline authors note those products can expand options in hard-to-treat cancers but often come with more limited efficacy datasets and tighter use restrictions. (merck-animal-health.com)
What to watch: Watch for additional studies aimed at full licensure, broader real-world use data, and whether published outcomes change how oncology specialists position gilvetmab in multimodal treatment plans. (merck-animal-health.com)
Key facts
- Drug
- Gilvetmab
- Type
- Caninized anti-PD-1 monoclonal antibody
- Species
- Dogs
- Indications
- Melanoma and mast cell tumors
- Regulatory status
- Conditionally licensed by the USDA in the U.S.
- Publication date
- October 1, 2026
- Journals
- Journal of Veterinary Internal Medicine, and Journal of the American Veterinary Medical Association
- Clinical program size
- 51 dogs
- Availability
- Available to board-certified veterinary oncologists since 2023
Merck Animal Health is using two new peer-reviewed publications to strengthen the evidence base for gilvetmab, its caninized immune checkpoint inhibitor for dogs with melanoma and mast cell tumors. In a news release published October 1, 2026, the company said the papers appeared in the Journal of Veterinary Internal Medicine and the Journal of the American Veterinary Medical Association, and described gilvetmab as the first caninized anti-PD-1 checkpoint inhibitor for canine oncology. (merck-animal-health.com)
The announcement builds on a product that has been on the U.S. market for several years under a different regulatory framework than most companion animal oncology drugs. USDA APHIS lists gilvetmab under product code 979002 for canine mast cell cancer and melanoma, with Intervet Inc. as the establishment and an approval date of August 29, 2019. Merck later announced in October 2023 that gilvetmab was available to veterinary specialists practicing oncology nationwide. (aphis.usda.gov)
The newly highlighted JVIM paper focuses on efficacy and safety in dogs with melanoma and mast cell tumor. Merck said the study assessed objective response rates, disease control, safety parameters, and immunologic dynamics in oral and cutaneous melanoma and mast cell tumor. The USDA product-summary document provides additional background on the clinical program, describing 51 enrolled dogs, including 26 with mast cell tumor and 25 with melanoma, treated by IV infusion at 14- or 28-day intervals for up to 10 total treatments. Merck’s 2023 availability announcement said initial trials showed tumor shrinkage or stable disease in 73% of dogs with mast cell tumor and 60% of dogs with melanoma over a 20-week trial, figures that helped shape early clinical interest. (merck-animal-health.com)
Safety remains part of the story. In the USDA summary, commonly reported adverse events in mast cell tumor cases included lethargy, weight loss, reduced appetite, vomiting, and diarrhea, while melanoma cases also frequently showed lethargy, reduced appetite, diarrhea, weight loss, and vomiting. The same document notes dogs were pretreated with diphenhydramine and monitored for six hours after treatment, underscoring that administration and follow-up are more involved than a simple outpatient injection. (aphis.usda.gov)
The second paper, published in JAVMA, appears to serve more as a broader scientific and clinical framing of checkpoint inhibition in canine cancer than as a pivotal efficacy report. Merck said it outlines how immune checkpoint inhibitors are emerging in veterinary oncology by reversing tumor-driven immune suppression. That message aligns with the 2026 AAHA oncology guidelines, which describe gilvetmab as a caninized monoclonal antibody against canine PD-1 and note that it is conditionally licensed by the USDA for dogs with mast cell tumors or melanoma, available only through veterinary specialists practicing oncology, with studies ongoing for full licensure. (merck-animal-health.com)
Industry reaction in the material reviewed was mostly company-led rather than independent outside commentary. Merck executives and affiliated veterinarians positioned the publications as a step toward evidence-based use in practice, and the JVIM paper’s PubMed record discloses company involvement and paid advisory or speaking relationships for at least one investigator. That doesn’t negate the findings, but it is important context for clinicians weighing how much to rely on sponsor-generated evidence versus independent validation and real-world experience. (merck-animal-health.com)
Why it matters: For veterinary professionals, this is less about a brand-new therapy and more about maturation of the evidence base around a novel class. Checkpoint inhibition has transformed parts of human oncology, but veterinary clinicians have had comparatively little peer-reviewed clinical data to guide case selection, expectations, monitoring, and conversations with pet parents. The publications could help oncologists better define where gilvetmab fits relative to surgery, radiation, Palladia, and other multimodal approaches. At the same time, the regulatory status still matters: AAHA notes that USDA-regulated biologics can be valuable in difficult cancers, but their efficacy data may be less extensive, and practices need to stay within label restrictions and maintain appropriate records. (aaha.org)
What to watch: The next signal will be whether Merck or independent investigators publish more granular outcome data, combination-therapy results, or real-world studies that support full licensure and wider adoption, especially as ongoing work explores gilvetmab in additional settings such as combination treatment protocols. (merck-animal-health.com)